Pressure Is Not a Personal Problem — Organizational Design That Stops Good Intentions from Becoming Violations

The MR who told a physician "prescribe two tablets at half the daily limit for 14 days and you effectively get a 28-day supply" was not trying to dismantle drug regulations. Two weeks left in the quarter, a competitor already entrenched at the account, and the pressure to do something drove the words out. Reading 186 violation cases across seven years, the root is not weak individual ethics — it is how organizations have designed pressure into their structures. This final chapter breaks down that structure concretely and asks what conditions prevent good intentions from producing violations.

So What / So Why — The Core of This Chapter

Across the nine categories and 186 cases tracked in this series, one starting point recurs. The people involved believed they were delivering a drug that would help patients. They felt they were doing the right thing even as they crossed the line. The four deep psychological drivers that appeared repeatedly from the introduction through the preceding chapter — motivated reasoning, local rationalization, errors of omission, and externalization of responsibility — did not activate because individuals were unusually weak. They activated because the pressure structures that trigger them were embedded in the organization.

The FY2025 surveillance report stated explicitly that "in some companies dealing with highly competitive drugs, cases were observed that suggested organizations were systematically conducting inappropriate promotional information activities." These were not MR slip-of-the-tongue errors or knowledge gaps. Violations aligned at the level of the sales organization as a whole were confirmed. Adding another checklist or more training hours does not reach this structure.

The fatal pattern is that the response to violations always ends in after-the-fact "education reinforcement." The same findings appear in the surveillance reports year after year for seven years — inadequate MR training, insufficient material review, COI disclosure reduced to a formality. If the problem were knowledge, education would solve it. But as long as the morning meeting runs on "push this month's numbers," the same pressure shapes behavior by evening. The design failure is what needs to be named.

The Structure of Pressure — Who, What Deadline, What Numbers

Breaking down pharmaceutical marketing by pressure source reveals seven layers. Each operates alone, but when several overlap, resistance drops fast.

① Quarterly sales and share targets. MR achievement rates are typically evaluated on a quarterly cycle. The final two weeks of a quarter are the highest-risk window. Once someone can calculate exactly how many new accounts would get them to target, the content of verbal explanations begins to shift. Most of the unsupported efficacy claims documented in this series (vol-03) were generated in this window.

② Early post-launch prescription volume expectations. Immediately after a new drug launch, product teams carry a KPI called "launch speed." Prescription day restrictions — in principle, no more than 14 days per prescription during the first year after approval — put direct pressure on that expectation. The explanation "two-tablet dosing at half the daily limit effectively allows long-term prescribing" appeared in multiple years and across multiple products over the seven-year record because launch deadline pressure repeatedly produced the same behavior.

③ Maintaining KOL relationships. Relationships with prominent physicians at academic medical centers directly affect product adoption. When a KOL speaks at a company-sponsored symposium, the account manager feels that "it's hard to question what the doctor says." The FY2025 allergy drug case — where pre-review by the promotional oversight department was skipped "because there was no time to confirm" — almost certainly had this asymmetric dynamic in the background.

④ Competitive pressure and the demand to differentiate. The more a competitor is already entrenched at an account, the harder MRs are pushed to "explain the difference." One reason competitor disparagement (vol-07) rose sharply in FY2024–2025 is that intensifying competition increased demand for explanations that create separation. The judgment that "a scientifically accurate statement can still be disparagement depending on intent" dulls the more differentiation is the focus.

⑤ The ambiguity of manager approval. "My manager was there too." "This is a slide the division head approved." These phrases appear repeatedly in individual violation cases. When manager sign-off functions as a device to distribute responsibility, individual accountability diffuses. The more layers an approval process has, the further externalization of responsibility (the fourth driver) progresses.

⑥ Distorted incentive design. Under a compensation system tied to short-term sales, conveying safety information carefully does not contribute directly to target achievement. "I didn't raise side effects because no one asked" (errors of omission, vol-06) is the logical outcome of this structure. When incentives reward emphasizing efficacy and do not penalize imbalance, behavior tilts.

⑦ Caught between regulation and the field. The information standards set by guidelines and the need physicians express in the field — "explain this in more detail" — sometimes come into genuine tension. The FY2025 report also recorded feedback from clinical settings that "the number of representatives becoming overly cautious about providing information has increased." Overcorrection is also a problem. With no clear line on what is permitted, representatives swing between regulatory requirements and what is expected of them.

Reconstructing the Inner State — Beliefs, Feelings, Deep Drivers

Here we reconstruct the inner experience of one MR using the insomnia drug case (FY2021) as material. This is the thought process of the representative who told a physician: "By prescribing two tablets at half the daily approved upper limit for 14 days, you can effectively achieve a 28-day supply."

Beliefs (what the person held to be right): "This drug improves sleep and raises patients' quality of life. Making someone with a sleep disorder come in twice a month because of a regulatory restriction is a burden. The physician must feel the same way." This belief starts from a genuinely patient-centered motive. That is not a violation in itself.

Feelings (the emotional state in the moment): At an account where a competitor was already adopted, with three weeks left in the quarter, the representative was carrying real pressure. A sense of urgency — "I have to show some kind of opening" — converged with a conviction that "the doctor will find this information useful." The feeling of doing something good pushed caution down.

Deep drivers (the four mechanisms at work): First, motivated reasoning engaged. The conclusion that "this drug is good" came first, and the information that "the purpose of prescription day restrictions is post-marketing safety surveillance" was filtered out as something that would undermine that conclusion. Then local rationalization added itself: "Two-tablet dosing is within the approved dosage range, so I'm not saying anything illegal" — viewed at the level of a single explanation unit, it looked legitimate. That the explanation meant hollowing out the intent of the restriction did not register. Errors of omission worked quietly alongside: the representative did not mention the reason the restriction exists — that safety data is limited in the first year after approval. No one asked, so nothing was said. Finally, externalization of responsibility completed the chain: "The physician makes the final prescribing decision. If the physician chose two-tablet dosing, that is the physician's medical judgment." All four drivers operated in sequence, and a behavior that began with the genuine intention to help patients landed as a dismantling of the prescription day restriction system.

This chain is not exceptional. The unsupported efficacy claims (vol-03), the omission of safety information (vol-06), and the hollow COI disclosures (vol-08) all trace the same path: beliefs, feelings, deep drivers. The design failure is the absence of any structure that interrupts this path.

The Underlying Incidents

Case 1: Allergy Drug — Company-Sponsored Symposium (FY2025, Document No. 001520054)

Case 2: Insomnia Drug — MR Verbal Explanation (FY2021, Document No. 000819797)

Case 3: (No specific product) — Manufacturer-Sponsored Web Seminar (FY2021, Document No. 000819797)

Testimony to Organizational Violation

The FY2025 report's statement that "there were cases that suggested intentional efforts at the sales organization level" directly supports the central argument of this chapter. This is not something that adequate ethics training for individuals would have prevented. When manager approval, organizational direction, and incentive design all point the same way, even well-trained representatives produce violations as collective behavior.

Four Conditions That Keep Good Intentions From Becoming Violations

The design failures that emerge across seven years, 186 cases, and nine categories flip into four conditions.

Condition 1: Psychological safety — an environment where "something seems wrong here" can be said. When a representative senses that "this explanation might be a problem," does the organization have a culture where that can be raised with a manager or the oversight department? A manager who pressures the team to "push the numbers" at the morning meeting and then says "stop if something feels wrong" the same afternoon — there is no ambiguity about which message drives evening behavior. If reporting a violation lowers someone's performance rating, problems go underground. Most of the safety information omissions in vol-06 happened inside an atmosphere where speaking up was hard.

Condition 2: Audit independence — a structure that prevents the oversight department from reaching predetermined conclusions. When the promotional information oversight department sits under a division that owns sales targets, review becomes procedural. The FY2025 allergy drug case shows a prior-review process that existed but was bypassed with "there was no time." A process existing and a process functioning are two different things. What matters is whether the oversight department has genuine independence, and whether skipping a review carries a real cost.

Condition 3: Incentive redesign — building axes other than short-term sales into evaluation. Without a structure that rewards balanced information provision covering both efficacy and safety, errors of omission will keep occurring structurally. Under an incentive design where carefully explaining side effects and losing an adoption is rated negatively, while emphasizing efficacy and gaining an adoption is rated positively, training has limited reach. Adding patient outcome metrics or physician satisfaction with information quality to the evaluation framework changes the direction of the incentive.

Condition 4: Culture, not checklists — sharing the reason behind each rule. Checklists are the last net, but checklists alone do not stop motivated reasoning. When representatives can explain in their own words why the prescription day restriction exists, or why COI disclosure is necessary to give an audience the context it needs to evaluate information credibly, the space for local rationalization shrinks. In every case across seven years, workarounds that hollowed out a rule's intent did so by observing the form of the rule while departing from its purpose. Understanding the purpose is the final line of defense.

These four conditions are not technical prescriptions. They are a declaration about what kind of organization a company wants to be. The difference between a company that chases numbers alone and one that tries to be an honest conduit of patient information does not show up in posters or compliance training — it shows up in how evaluation and approval actually work every day.